Turkkan, GorkemDogan, CanerTek, Burak2024-06-122024-06-1220201078-15521477-092Xhttps://doi.org/10.1177/1078155219886918https://hdl.handle.net/20.500.14551/19061Introduction Bicalutamide is widely used in the treatment of prostate cancer. Among its side effects, central nervous system disorders are relatively rare, and the information about bicalutamide-associated hallucinations is limited. Case report We report an uncommon case of a patient with metastatic prostate cancer, who had hallucinations due to the use of bicalutamide. Management and outcome The patient accepted to receive only hormonal therapy (bicalutamide and leuprolide acetate). But he developed hallucinations due to bicalutamide use. His hallucinations disappeared after discontinuation of bicalutamide. A good response was obtained with the use of luteinizing hormone-releasing hormone agonist monotherapy. Discussion The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.en10.1177/1078155219886918info:eu-repo/semantics/closedAccessBicalutamideHallucinationsProstate CancerAndrogen Deprivation TherapyReelinArticle26410291031Q4WOS:00049608950000131707924